CAR T-Cells, Helping US Firms & An “Ambitious” Plan For Advanced Therapies In The EU
Executive Summary
As companies like Novartis, bluebird bio and Kite Pharma press on with developing cancer treatments based on cutting edge CAR T-cell technology, the new chair of the European Medicines Agency’s Committee for Advanced Therapies, Martina Schüssler-Lenz, tells the Pink Sheet about plans to help makers of these and other innovative advanced therapies.
You may also be interested in...
EMA Reviewing Guide To Support New Genome Editing Technologies, CAR-T Cell Therapies
The European Medicines Agency is updating its five-year old guideline on drugs containing genetically modified cells to factor in rapid scientific developments in relation to gene editing technologies, and the development of promising new cancer immunotherapies, such as CAR-T cells.
CAR-T Cancer Drugs Front And Center At ARM Investor Day
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.